| 2025-12-09 |
详情>>
内部人交易：
Stueland Katherine等共交易4笔
|
| 2025-10-28 |
详情>>
股本变动：
变动后总股本2890.46万股
|
| 2025-10-28 |
详情>>
业绩披露：
2025年三季报(累计)每股收益-0.12美元,归母净利润-335.5万美元,同比去年增长94.19%
|
| 2025-10-28 |
财报披露：
美东时间 2025-10-28 盘前发布财报
|
| 2025-07-29 |
详情>>
业绩披露：
2025年中报每股收益0.15美元,归母净利润428.00万美元,同比去年增长108.66%
|
| 2025-04-30 |
股东大会：
将于2025-06-18召开股东大会
会议内容 ▼▲
- 1.Elect two Class I directors, each to serve until the 2028 annual meeting of stockholders and until his or her successor has been elected and qualified;
2.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025;
3.Transact any other business that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2025-04-30 |
详情>>
业绩披露：
2025年一季报每股收益-0.23美元,归母净利润-652.9万美元,同比去年增长67.74%
|
| 2025-02-20 |
详情>>
业绩披露：
2024年年报每股收益-1.94美元,归母净利润-5228.6万美元,同比去年增长70.25%
|
| 2024-10-29 |
详情>>
业绩披露：
2024年三季报(累计)每股收益-2.17美元,归母净利润-5772.4万美元,同比去年增长61.52%
|
| 2024-07-31 |
复牌提示：
2024-07-31 09:33:06 停牌，复牌日期 2024-07-31 09:38:06
|
| 2024-07-30 |
详情>>
业绩披露：
2024年中报每股收益-1.88美元,归母净利润-4941.2万美元,同比去年增长54.12%
|
| 2024-04-29 |
股东大会：
将于2024-06-20召开股东大会
会议内容 ▼▲
- 1.To elect three Class III directors of the Company, each to serve a three-year term expiring at the Company’s 2027 annual meeting of stockholders and until such director’s successor is duly elected and qualified (“Proposal No. 1”);
2.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2024 (“Proposal No. 2”);
3.To transact such other business as may properly come before the Annual Meeting or any adjournment or postponement thereof.
|
| 2024-04-29 |
详情>>
业绩披露：
2024年一季报每股收益-0.78美元,归母净利润-2023.9万美元,同比去年增长66.82%
|
| 2024-02-23 |
详情>>
业绩披露：
2023年年报每股收益-7.23美元,归母净利润-1.76亿美元,同比去年增长67.98%
|
| 2023-11-03 |
详情>>
业绩披露：
2023年三季报(累计)每股收益-6.31美元,归母净利润-1.5亿美元,同比去年增长37.56%
|
| 2023-08-08 |
详情>>
业绩披露：
2023年中报每股收益-4.73美元,归母净利润-1.08亿美元,同比去年增长33.77%
|
| 2023-04-28 |
股东大会：
将于2023-06-14召开股东大会
会议内容 ▼▲
- 1.Elect two Class II directors, each to serve until the 2026 annual meeting of stockholders and until his or her successor has been elected and qualified.
2.Ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023.
3.Transact any other business that may properly come before the Annual Meeting or any adjournments or postponements thereof.
|
| 2023-04-28 |
详情>>
拆分方案：
每33.0000合并分成1.0000股
|
| 2023-03-31 |
股东大会：
将于2023-04-14召开股东大会
会议内容 ▼▲
- 1.To approve an amendment to our third amended and restated certificate of incorporation, as amended (the “Charter”), to effect a reverse stock split of our outstanding shares of Class A common stock, par value $0.0001 per share (“Class A Common Stock”), at a ratio, ranging from one-for-ten (1:10) to one-for-fifty (1:50), with the exact ratio to be set within that range at the discretion of our board of directors (the “Board”) without further approval or authorization of our stockholders;
2.To approve an amendment to the Charter to limit the liability of certain officers of the Company as permitted pursuant to recent amendments to the Delaware General Corporation Law;
3.To approve for purposes of complying with Nasdaq Listing Rule 5635(d), the issuance of 22,336,624 shares of Class A Common Stock in connection with the Company’s previously announced $150.0 million offerings of Class A Common Stock;
4.To approve an amendment to the Company’s 2021 Equity Incentive Plan (the “2021 EIP”) to increase the aggregate number of shares of Class A Common Stock authorized for issuance under the Plan by 26,000,000 shares
5.To approve a proposal to adjourn the Special Meeting to a later date or dates, if necessary or appropriate, to permit further solicitation and vote of proxies in the event that there are insufficient votes for, or otherwise in connection with, the approval of the Reverse Stock Split Proposal, the Officer Exculpation Proposal or the Stock Issuance Proposal.
|
| 2022-03-31 |
股东大会：
将于2022-04-27召开股东大会
会议内容 ▼▲
- 1.For purposes of complying with applicable Nasdaq Stock Market (the “Nasdaq”) listing rules (the “Nasdaq Listing Rules”), to approve the issuance of the Company’s Class A common stock, par value $0.0001 per share (the “Class A common stock”), in connection with the Acquisition (as defined in the accompanying proxy statement) and as contemplated by the Agreement and Plan of Merger and Reorganization dated January 14, 2022 (the “Merger Agreement”), by and among the Company, GeneDx, Inc. (“GeneDx”), a wholly-owned subsidiary of OPKO Health, Inc. (“OPKO”), OPKO, Orion Merger Sub I, Inc. (“Merger Sub I”), a wholly-owned subsidiary of the Company, Orion Merger Sub II, LLC (“Merger Sub II” and together with Merger Sub I, “Merger Subs”), a wholly-owned subsidiary of the Company, and GeneDx Holding 2, Inc., which will own 100% of GeneDx at the Effective Time (as defined in the accompanying proxy statement) (“HoldCo”);
2.For purposes of complying with the Nasdaq Listing Rules, to approve the issuance of the Class A common stock in connection with the PIPE Investment (as defined in the accompanying proxy statement) and as contemplated by the Subscription Agreements (as defined in the accompanying proxy statement);
3.Assuming the Stock Consideration Issuance Proposal and the Charter Amendment Proposal are approved and adopted and the Acquisition is consummated, to appoint two directors who will become directors of the Company effective upon the consummation of the Acquisition;
4.To adopt an Amendment (the “Amendment”) to the Third Amended and Restated Certificate of Incorporation of the Company, in the form attached hereto as Annex B (the “Charter”), which increases the number of authorized shares of Class A common stock from 380,000,000 to 1,000,000,000;
5.To elect three Class I directors of the Company, each to serve a three-year term expiring at the Company’s 2025 annual meeting of stockholders and until such director’s successor is duly elected and qualified;
6.To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2022;
7.To approve, if necessary, the adjournment of the Special Meeting to a later date or dates to permit further solicitation and votes of proxies in the event that there are insufficient votes for, or otherwise in connection with any of the proposals presented at the Special Meeting.
|